fda ruling on glp 1 says that the GLP-1 shortage is over Readout Newsletter: FDA GLP-1 labels,
Description
Mol Cell Endocrinol 418:4254 Lorenz M, Evers A, Wagner M (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity

All GLP-1 medications require physician evaluation and oversight
Personalizing Hormone Replacement Therapy and GLP-1 Combinations The Lancet data make the case for combination therapy in quantitative terms
10.2337/dc22-1889 [DOI] [PMC free article] [PubMed] [Google Scholar] 71

Clinical Safety and Considerations While the combination is generally considered safe, it is not appropriate for everyone
